Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cel...
Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cells
About this item
Full title
Author / Creator
Publisher
England: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Patients with triple‐negative breast cancers (TNBCs) typically have a poor prognosis because such cancers have no effective therapeutic targets, such as estrogen receptors for endocrine therapy or human epidermal growth factor receptor 2 (HER2) receptors for anti‐HER2 therapy. As the phosphatidylinositol 3′ kinase (PI3K)/Akt/mammalian target of rap...
Alternative Titles
Full title
Efficacy of everolimus, a novel mTOR inhibitor, against basal‐like triple‐negative breast cancer cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7659327
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7659327
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/j.1349-7006.2012.02359.x
